Log in
Enquire now
‌

US Patent 7659384 Polynucleotides encoding fully human antibodies against human 4-1BB

Patent 7659384 was granted and assigned to Bristol-Myers Squibb on February, 2010 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent

Patent attributes

Current Assignee
Bristol-Myers Squibb
Bristol-Myers Squibb
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
7659384
Date of Patent
February 9, 2010
Patent Application Number
11903106
Date Filed
September 20, 2007
Patent Citations Received
‌
US Patent 11999800 Bispecific and tetravalent CD137 and FAP molecules for the treatment of cancer
0
‌
US Patent 12065478 HER2-targeting antigen binding molecules comprising 4-1BBL
0
Patent Primary Examiner
‌
Ilia Ouspenski
Patent abstract

Fully human antibodies and antigen-binding portions thereof that bind to human 4-1BB and that allow binding of human 4-1BB to a human 4-1BB ligand. In one aspect, the antibody is an IgG4 antibody. Also provided is a method for treating a disease in a subject comprising administering a therapeutically effective amount of the antibody to said subject.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 7659384 Polynucleotides encoding fully human antibodies against human 4-1BB

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.